Menu
Back to Journals » Biologics: Targets and Therapy » Volume 13
Original Research
Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 12,260 | Dovepress* | 10,574+ | 781 | 11,355 | |
| PubMed Central* | 1,686 | 170 | 1,856 | ||
| Totals | 12,260 | 951 | 13,211 | ||
| *Since 25 November 2019 | |||||
View citations on PubMed Central and Google Scholar